{"id":71963,"date":"2018-11-17T01:00:00","date_gmt":"2018-12-07T05:00:59","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/12\/07\/4d6642245b\/"},"modified":"2018-12-07T13:01:00","modified_gmt":"2018-12-07T05:01:00","slug":"4d6642245b","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/71963\/","title":{"rendered":"\u963f\u65af\u5229\u5eb7PD-L1\u91cd\u78c5\u68a6\u788e\uff1f\uff01MYSTIC\u8bd5\u9a8c\u5ba3\u544a\u5931\u8d25"},"content":{"rendered":"
\n

\"\u963f\u65af\u5229\u5eb7PD-L1\u91cd\u78c5\u68a6\u788e\uff1f\uff01MYSTIC\u8bd5\u9a8c\u5ba3\u544a\u5931\u8d25\"<\/p>\n


<\/p>\n

\n
\n
\n
\n
\n
\"\u963f\u65af\u5229\u5eb7PD-L1\u91cd\u78c5\u68a6\u788e\uff1f\uff01MYSTIC\u8bd5\u9a8c\u5ba3\u544a\u5931\u8d25\"<\/p>\n
\u7acb\u523b\u626b\u7801\uff01<\/strong><\/section>\n<\/section>\n
\n

\u7275\u624b\u533b\u5c4a\u5927\u5496<\/span><\/strong><\/span><\/p>\n

\u805a\u7126\u5b66\u672f\u524d\u6cbf<\/span><\/strong><\/p>\n

\u8bf7\u5173\u6ce8
<\/strong><\/span><\/p>\n

\u5b50\u53f7\u201c\u514d\u75ab\u65f6\u95f4<\/span>\u201d<\/strong><\/span><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\"\u963f\u65af\u5229\u5eb7PD-L1\u91cd\u78c5\u68a6\u788e\uff1f\uff01MYSTIC\u8bd5\u9a8c\u5ba3\u544a\u5931\u8d25\"<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\n

\u6765\u6e90\uff1a\u514d\u75ab\u65f6\u95f4<\/span>
<\/p>\n<\/blockquote>\n


<\/p>\n

11\u670816\u65e5\uff0c\u963f\u65af\u5229\u5eb7\u5b98\u7f51\u53d1\u5e03\u300aAstraZeneca provides update on the Phase III MYSTIC trial of Imfinziand tremelimumab in Stage IV non-small cell lung cancer<\/em>\u300b\uff0c<\/span>\u516c\u5e03\u5176\u5907\u53d7\u5168\u7403\u5173\u6ce8\u7684MYSTIC\u8bd5\u9a8c\u7ed3\u679c\uff0c\u6700\u7ec8\u6ca1\u6709\u8fbe\u5230\u6539\u5584\u603b\u751f\u5b58\u671f\uff08OS\uff09\u7684\u7814\u7a76\u7ec8\u70b9\uff0c\u6570\u636e\u4e0d\u5177\u5907\u7edf\u8ba1\u5b66\u610f\u4e49\u3002<\/strong><\/span><\/p>\n


<\/span><\/p>\n

\u8d44\u6599\u8fdb\u4e00\u6b65\u663e\u793a:\u91c7\u7528Imfinzi\u5355\u836f\u6cbb\u7597\u7684\u98ce\u9669\u6bd4\uff08HR\uff09\u4e3a0.76(97.54%CI 0.564-1.019; nominal p=0.036)\uff0c\u91c7\u7528Imfinzi +tremelimumab\u8054\u5408\u6cbb\u7597\u7684\u98ce\u9669\u6bd4\u4e3a0.85 (98.77% CI 0.611-1.173;nominal p=0.202)\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u4e1a\u5185\u4eba\u58eb\u6307\u51fa\uff0c\u4f5c\u4e3a\u963f\u65af\u5229\u5eb7IO\u9886\u57df\u7684\u57fa\u77f3\u4ea7\u54c1\uff0c2017\u5e745\u6708\u8be5\u836f\u4e0a\u5e02\u540e\uff0c\u53bb\u5e74\u9500\u552e\u989d\u4e3a0.19\u4ebf\u7f8e\u5143\uff0c2018\u4e0a\u534a\u5e74\u9500\u552e\u989d\u589e\u957f\u9887\u4e3a\u7f13\u6162\u3002\u201c<\/span>\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u5728\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u9886\u57df\u4e2a\u522b\u9879\u76ee\u6298\u621f\uff0c\u5c06\u5728\u4e00\u5b9a\u7a0b\u5ea6\u5bf9\u5e02\u573a\u7aef\u9020\u6210\u5f71\u54cd\uff0cImfinzi\u6210\u4e3a\u8d85\u7ea7\u91cd\u78c5\u7684\u68a6\u60f3\u53ef\u80fd\u6e10\u884c\u6e10\u8fdc\u3002<\/strong><\/span>\u201d<\/span><\/p>\n


<\/span><\/p>\n

\n


<\/p>\n

\n
\n
\n
\u963f\u65af\u5229\u5eb7\uff1a<\/span><\/strong><\/section>\n
\n
\n

                    <\/span><\/strong> \u5bf9\u4e8e\u7ed3\u679c\u975e\u5e38\u5931\u671b<\/span><\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u80ba\u764c\u662f\u5168\u7403\u764c\u75c7\u6b7b\u4ea1\u7684\u4e3b\u8981\u539f\u56e0\uff0c\u7ea6\u5360\u6bcf\u5e74\u65b0\u53d1\u764c\u75c7\u75c5\u4f8b\u768412.9%\uff0c\u5168\u7403\u6bcf\u5e74\u6709\u8fd1160\u4e07\u4eba\u6b7b\u4e8e\u80ba\u764c\u3002<\/span>\u6839\u636e\u7f8e\u56fd\u764c\u75c7\u5b66\u4f1a\uff08AmericanCancerSociety\uff09\u53d1\u5e03\u7684\u300a2017\u764c\u75c7\u7edf\u8ba1\u300b\uff08Cancer Facts & Figures 2017\uff09\u62a5\u544a\uff0c\u5728\u80ba\u764c\u4e2d\u5927\u7ea6\u670985%\u7684\u75c5\u4f8b\u662f\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff0c\u5b83\u4eec\u4ee5\u96be\u6cbb\u800c\u95fb\u540d\uff1b<\/span>\u5728\u6240\u6709\u7684\u80ba\u764c\u65b0\u53d1\u75c5\u4f8b\u4e2d\uff0c\u5927\u7ea6\u6709\u4e09\u5206\u4e4b\u4e00\u7684\u60a3\u8005\u5728\u5f97\u5230\u8bca\u65ad\u65f6\uff0c\u75c5\u60c5\u5df2\u7ecf\u53d1\u5c55\u5230\u4e86III\u671f\uff0c\u8fd1\u4e00\u534aIII\u671f\u80ba\u764c\u60a3\u8005\u7684\u80bf\u7624\u65e0\u6cd5\u5207\u9664\uff0c\u9884\u540e\u60c5\u51b5\u4e0d\u5bb9\u4e50\u89c2\uff0c5\u5e74\u751f\u5b58\u7387\u5e73\u5747\u53ea\u670910%-23%\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u663e\u7136\uff0c\u5982\u679c\u4ea7\u54c1\u80fd\u591f\u5728NSCLC\u5404\u7c7b\u5206\u671f\u4e2d\u5f97\u5230\u6ee1\u610f\u7684\u6cbb\u7597\u6548\u679c\uff0c\u5373\u53ef\u6ee1\u8db3\u5de8\u5927\u7684\u672a\u88ab\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\uff0c\u5e02\u573a\u6f5c\u529b\u4e0d\u53ef\u5c0f\u89d1\u3002<\/span><\/p>\n


<\/span><\/p>\n

MYSTIC \u7814\u7a76\u662f\u4e00\u9879\u968f\u673a\u3001\u5f00\u653e\u6807\u7b7e\u3001\u56fd\u9645\u591a\u4e2d\u5fc3\u7684Phase III\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/span><\/strong><\/span>Clinicaltrials.gov\u663e\u793a\uff0cMYSTIC\u8bd5\u9a8c\u8ba1\u5212\u5165\u7ec41118\u4f8b\u60a3\u8005\uff0c\u5728\u5168\u740317\u4e2a\u56fd\u5bb6\uff08\u5730\u533a\uff09\u7684167\u4e2a\u7814\u7a76\u673a\u6784\u5f00\u5c55\uff0c\u5176\u4e2d\u5305\u62ec\u65e5\u672c\u3001\u97e9\u56fd\u3001\u6cf0\u56fd\u3001\u8d8a\u5357\u548c\u53f0\u6e7e\u7b49\u4e9a\u6d32\u56fd\u5bb6\uff08\u5730\u533a\uff09\u7684\u7814\u7a76\u5355\u4f4d\uff0c\u65e8\u5728\u63a2\u7d22\u963f\u65af\u5229\u5eb7PD-L1\u660e\u661f\u54c1\u79cdImfinzi (durvalumab)\u5355\u836f\u6216Imfinzi \u8054\u5408tremelimumab\uff0c\u4e0e\u6807\u51c6\u6cbb\u7597\u542b\u94c2\u5316\u7597\u65b9\u6848\u76f8\u6bd4\u8f83\uff0c\u5728\u672a\u7ecf\u6cbb\u7597\u7684\u8f6c\u79fb\u6027\uff08stage IV\uff09\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7684\u6cbb\u7597\u5b89\u5168\u6027\u4e0e\u6709\u6548\u6027\u3002<\/span><\/p>\n


<\/span><\/p>\n

2017<\/span>\u5e747\u6708\u4efd\uff0c\u963f\u65af\u5229\u5eb7\u66fe\u5bf9\u5916\u5ba3\u5e03MYSTIC III\u671f\u4e34\u5e8a\u7814\u7a76\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08PFS\uff09\u672a\u80fd\u8fbe\u5230\u9884\u5148\u8bbe\u5b9a\u7684\u4e3b\u8981\u7814\u7a76\u7ec8\u70b9\uff1a\u5728PD-L1\u80bf\u7624\u6bd4\u4f8b\u5f97\u5206\uff08TPS\uff09\u226525%\u7684\u60a3\u8005\u4e2d\uff0c\u4e0eSoC\u542b\u94c2\u5316\u7597\u76f8\u6bd4\uff0cImfinzi+tremelimumab\u514d\u75ab\u7ec4\u5408\u672a\u80fd\u8fbe\u5230\u6539\u5584PFS\u7684\u4e3b\u8981\u7ec8\u70b9\uff1b\u6b21\u8981\u7ec8\u70b9\u65b9\u9762\uff0c\u5c3d\u7ba1\u672a\u6b63\u5f0f\u8bc4\u4f30\uff0c\u4f46\u5df2\u521d\u6b65\u5f97\u51faImfinzi\u5355\u836f\u7597\u6cd5\u76f8\u5bf9SoC\u4e0d\u4f1a\u8fbe\u5230\u9884\u5148\u8bbe\u5b9a\u7684PFS\u53d7\u76ca\u9608\u503c\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u7ee7\u7eed\u8bc4\u4f30Imfinzi\u5355\u836f\u7ec4\u548cImfinizi\u8054\u5408\u7ec4\u7684\u53e6\u5916\u4e24\u4e2a\u4e3b\u8981\u7814\u7a76\u7ec8\u70b9\u603b\u751f\u5b58\u671f\uff08OS\uff09\uff0c\u4fbf\u6210\u4e3a\u5224\u65ad\u8bd5\u9a8c\u6700\u7ec8\u6210\u8d25\u7684\u5173\u952e<\/span><\/strong>\u3002<\/span>\u76ee\u524d\uff0cImfinzi\u5c1a\u672a\u6279\u51c6\u7528\u4e8e\u80ba\u764c\u6cbb\u7597\uff0c\u800c\u963f\u65af\u5229\u5eb7\u8d77\u521d\u5bf9\u8fd9\u4e00\u5173\u952e\u6027\u7ed3\u679c\u5bc4\u4e88\u539a\u671b\uff0c\u7136\u800c\uff0c\u73b0\u5b9e\u662f\u6b8b\u9177\u7684\uff0c\u5bf9\u4e8e\u6ca1\u6709\u7edf\u8ba1\u5b66\u610f\u4e49\u7684\u8bd5\u9a8c\u7ed3\u5c40\uff0c\u5b98\u65b9\u8868\u793a\u5341\u5206\u5931\u671b\u3002<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\u5e02\u573a\u5224\u65ad\uff1a<\/span><\/strong><\/section>\n
\n
\n

                     <\/span><\/strong> \u7ec6\u5206\u9886\u57df\u7ade\u4e89\u52a0\u5267<\/span><\/strong><\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

Imfinzi\uff08durvalumab\uff09\u662f\u4e00\u79cdPD-L1\u514d\u75ab\u7597\u6cd5\uff0c\u9776\u5411\u7ec6\u80de\u7a0b\u5e8f\u6027\u6b7b\u4ea1\u56e0\u5b50\u914d\u4f531\uff08PD-L1\uff09<\/span><\/strong><\/span>\uff0c\u8be5\u4ea7\u54c1\u662fPD-1\/PD-L1\u514d\u75ab\u6cbb\u7597\u9886\u57df\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c5\u4e2a\u4ea7\u54c1\uff0c\u540c\u65f6\u4e5f\u662f\u7ee7\u7f57\u6c0f\u3001\u9ed8\u514b\/\u8f89\u745e\u540e\u4e0a\u5e02\u7684\u7b2c\u4e09\u4e2aPD-L1\u514d\u75ab\u7597\u6cd5\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u5728\u5df2\u4e0a\u5e02\u76845\u4e2a\u4ea7\u54c1\u4e2d\uff0c\u8f89\u745e\u548c\u9ed8\u514b\u8054\u5408\u5f00\u53d1\u7684PD-L1\u6297\u4f53avelumab\uff0c\u57282017\u5e74\u5e95\u548c\u4eca\u5e742\u6708\u9646\u7eed\u53d1\u5e03\u7684\u4e00\u9879\u80c3\u764c\u4e09\u671f\u3001\u4e00\u9879\u80ba\u764c\u4e09\u671f\u8bd5\u9a8c\uff0c\u5747\u4ee5\u5931\u8d25\u544a\u7ec8\uff0c\u7ed9avelumab\u7684\u524d\u666f\u8499\u4e0a\u4e86\u9634\u5f71\u3002\u76f8\u6bd4avelumab\u7684\u5931\u610f\uff0c\u5176\u4f59\u54c1\u79cd\u6b64\u524d\u5747\u5728\u591a\u4e2a\u764c\u75c7\u9886\u57df\u6709\u6240\u7a81\u7834\uff0c\u5e02\u573a\u9884\u671f\u9887\u4e3a\u5149\u660e\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u5728\u7f8e\u56fd\uff0cImfinzi\u4e8e2017\u5e745\u6708\u83b7\u5f97\u7f8e\u56fdFDA\u6279\u51c6\u7528\u4e8e\u65e2\u5f80\u5df2\u63a5\u53d7\u6cbb\u7597\u7684\u5c40\u90e8\u665a\u671f\u6216\u8f6c\u79fb\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\uff08mUC\uff09\u60a3\u8005\u7684\u6cbb\u7597\u3002\u6b64\u524d\uff0c\u963f\u65af\u5229\u5eb7\u53d1\u5e03\u7684 PACIFIC \u4e34\u5e8a\u8bd5\u9a8c\u6570\u636e\u8868\u73b0\u79ef\u6781\uff0c\u8be5\u7814\u7a76\u8bc4\u4f30\u4e86Imfinzi\uff08durvalumab\uff09\u5728\u4e0d\u80fd\u624b\u672f\u5207\u9664\u7684III\u671fNSCLC\u60a3\u8005\u4e2d\u7684\u7597\u6548\uff0c\u7ed3\u679c\u53d1\u73b0\uff0c\u4e0e\u5b89\u6170\u5242\u76f8\u6bd4\uff0c\u63a5\u53d7Imfinzi\u7684\u60a3\u8005\u7684PFS\u548cOS\u5177\u6709\u7edf\u8ba1\u5b66\u548c\u4e34\u5e8a\u610f\u4e49\u663e\u8457\u6539\u5584\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u5e02\u573a\u65b9\u9762\uff0c\u7ec6\u5206\u9886\u57df\u7684\u7ade\u4e89\u785d\u70df\u4e0d\u65ad\uff0c\u9ed8\u6c99\u4e1c\u5df2\u6709Keytruda\u5728PD-L1\u9ad8\u8868\u8fbe\u548c\u4e0e\u5316\u7597\u8054\u7528\u5728\u6240\u6709NSCLC\u7684\u4e00\u7ebf\u6807\u7b7e\uff0c\u65bd\u8d35\u5b9d\u3001\u7f57\u6c0f\u7684\u5316\u7597\u7ec4\u5408\u4e5f\u864e\u89c6\u7708\u7708\uff1b\u963f\u65af\u5229\u5eb7Imfinzi\u5728NSCLC\u9886\u57df\u521a\u521a\u5f00\u59cb\u7ad9\u7a33\u811a\u8ddf\uff0c\u5c31\u5728MYSTIC\u8bd5\u9a8c\u4e2d\u7ffb\u8f66\uff0c\u4e0d\u7981\u4ee4\u4eba\u611f\u6168\u521b\u65b0\u53d1\u548c\u4e34\u5e8a\u5f00\u53d1\u4e4b\u8270\u96be\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u5931\u8d25\u6c38\u8fdc\u662f\u9636\u6bb5\u6027\u7684\uff0c\u4e5f\u7edd\u4e0d\u662f\u4e00\u4ef6\u53ef\u6015\u7684\u4e8b\u60c5\uff0c\u66f4\u4e0d\u5e94\u5f53\u56e0\u4e3a\u5bb3\u6015\u5931\u8d25\u800c\u5931\u53bb\u5bf9\u6210\u529f\u7684\u6e34\u671b\u548c\u4fe1\u5fc3\u3002\u76ee\u524d\uff0c<\/span>\u963f\u65af\u5229\u5eb7\u6b63\u5728\u5f00\u5c55\u5e7f\u6cdb\u7684\u4e34\u5e8a\u9879\u76ee\uff0c\u5728\u591a\u79cd\u80bf\u7624\u4e2d\u8c03\u67e5Imfinzi\u5355\u836f\u6cbb\u7597\u53ca\u4e0e\u5176\u4ed6\u836f\u7269\u7ec4\u5408\u6cbb\u7597\u7684\u6f5c\u529b\uff0c\u5305\u62ec\u5934\u9888\u764c\u3001\u80c3\u764c\u3001\u80f0\u817a\u764c\u3001\u8180\u80f1\u764c\u3001\u8840\u6db2\u80bf\u7624\u7b49\u3002<\/strong><\/span><\/p>\n


<\/span><\/p>\n

PD-1\/L1<\/span>\u836f\u7269\u7684\u98de\u901f\u8fdb\u5c55,\u4ee4\u5f88\u591a\u4eba\u5fd8\u8bb0\u4e86\u5176\u5b9e\u6211\u4eec\u5bf9\u8fd9\u4e00\u9886\u57df\u4f9d\u7136\u7f3a\u4e4f\u8db3\u591f\u7684\u7406\u89e3\u3002\u6bcb\u5eb8\u7f6e\u7591\uff0c\u65b0\u53d1\u662f\u5178\u578b\u7684\u9ad8\u6295\u5165\u3001\u9ad8\u98ce\u9669\u3001\u9ad8\u56de\u62a5\u7684\u79d1\u5b66\u63a2\u7d22\u884c\u4e3a\uff0c\u4efb\u4f55\u4e00\u4e2a\u4e34\u5e8a\u8bd5\u9a8c\u9879\u76ee\u90fd\u65e0\u6cd5\u9884\u6d4b\u7ed3\u679c\uff0c\u4f46<\/span>\u524d\u8def\u867d\u8270\uff0c\u552f\u6709\u7834\u98ce\u524d\u884c\uff0c<\/span>\u9762\u5bf9\u632b\u6298\u6211\u4eec\u4f9d\u7136\u6e34\u671b\u5947\u8ff9\u3002<\/span><\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

\u7acb\u523b\u626b\u7801\uff01 \u7275\u624b\u533b\u5c4a\u5927\u5496 \u805a\u7126\u5b66\u672f\u524d\u6cbf \u8bf7\u5173\u6ce8 \u5b50\u53f7\u201c\u514d\u75ab\u65f6\u95f4\u201d \u6765\u6e90\uff1a\u514d\u75ab\u65f6\u95f4 11\u670816\u65e5\uff0c\u963f\u65af\u5229\u5eb7\u5b98\u7f51\u53d1 […]<\/p>\n","protected":false},"author":1,"featured_media":71964,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/71963"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=71963"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/71963\/revisions"}],"predecessor-version":[{"id":71968,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/71963\/revisions\/71968"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/71964"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=71963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=71963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=71963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}